ADMA BIOLOGICS INC (ADMA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ADMA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ADMA | Chief Operating Officer | 62 | ["Over 30 years of biotech and pharmaceutical leadership experience","Commercialized products in the US, EU, Asia, and globally","Chief Commercial Officer at bluebird bio, Inc.","Roles at Bristol-Myers Squibb Company with increasing responsibility","Managed global P&Ls","Chair of the Alliance for Regenerative Medicine Gene Therapy Section"] | ["Governance and Nominations Committee","Compensation Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Ms. Finger has been a member of the Board since September 2023 and currently serves as a member of the Company s Governance and Nominations Committee and Compensation Committee. Ms. Finger has over 30 years of biotech and pharmaceutical leadership experience building and optimizing brands and portfolios in the areas of Gene Medicine, Cell Therapy, Oncology, Neurology, Virology, and Metabolics. She has commercialized products in the US, EU, Asia, and globally. Ms. Finger has served as Chief Operating Officer of Vicero, Inc. since September 2023, where she leads business operations, including strategic and financial planning, company build and business development. Ms. Finger previously was Chief Commercial Officer at bluebird bio, Inc. ( bluebird ) from August 2015 to January 2021, where she built the commercial business enterprise in both Europe and the US, and prepared bluebird s rst gene and cell therapy products for market. Prior to bluebird, from May 1993 until May 2014, Ms. Finger was at Bristol-Myers Squibb Company ( BMS ) in roles with increasing responsibility, leading franchises in Virology, Neurology, and Hematology/Oncology. In these roles she led portfolio planning, product development and franchise strategy, and global commercialization. Ms. Finger also served as Managing Director of BMS Australia/NZ and has managed country, regional, and global P&Ls. Ms. Finger serves as an independent director for KeifeRx LLC and previously served as an independent director for VBL Therapeutics (Nasdaq: VBLT) from July 2021 to August 2022 and for Decibel Therapeutics (Nasdaq: DBTX) from December 2021 until its acquisition in September 2023. As a director of Decibel Therapeutics, Ms. Finger served as Chair of the Nominating and Corporate Governance Committee and a member of the Audit Committee. She has been Chair of the Alliance for Regenerative Medicine Gene Therapy Section and served on the Board of the Alliance for Regenerative Medicine Foundation. Ms. Finger also served as a member of the board for The Medicines Australia Industry Association and Member of the Pharmaceutical Strategic Working Group for the Australia Senator for Industry and Innovation. Ms. Finger has a B.A. from St. Lawrence University and an M.B.A. from Duke University Fuqua School of Business. Ms. Finger s extensive experience as an executive in the biotech and pharmaceutical industry qualifies her to serve as a director of the Company.